Neovascular (wet) age-related macular degeneration (AMD); visual impairment due to macular oedema secondary to retinal vein occlusion (branch or central RVO); visual impairment due to diabetic macular oedema (DME); visual impairment due to myopic choroidal neovascularisation (myopic CNV).
Intravitreal injAdult Wet AMD 2 mg (50 microlitres). Initially 1 inj mthly for 3 consecutive doses, then extend treatment interval to 2 mth. Based on physician's judgment, treatment interval maybe further extended using a treat-&-extend dosing regimen, increasing inj intervals in 2- or 4-wkly increments to maintain stable visual &/or anatomic outcomes. Macular oedema secondary to RVO (branch or central RVO) 2 mg (50 microlitres). After initial inj, treatment is given mthly. Interval between 2 doses should not be shorter than 1 mth. DME 2 mg (50 microlitres). Intially 1 inj mthly for 5 consecutive doses, followed by 1 inj every 2 mth. Myopic CNV Single 2 mg (50 microlitres) inj. Additional doses may be given if visual &/or anatomic outcomes indicate that the disease persists. Interval between 2 doses should not be shorter than 1 mth.
Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract. Do not inj while IOP is ≥30 mmHg. Potential for immunogenicity. Reports of non-ocular haemmorhage & arterial thromboembolic events. Patients w/ history of stroke or transient ischaemic attacks or MI w/in the last 6 mth. Increased risk of systemic adverse events w/ bilateral treatment. Patients w/ risk factors for retinal pigment epithelial tears. Withhold treatment in cases of rhegmatogenous retinal detachment or stage 3 or 4 macular holes; retinal break; decreased best-corrected visual acuity (BCVA) of ≥30 letters compared w/ the last assessment of visual acuity; subretinal haemorrhage involving the centre of fovea, or if the size of haemorrhage is ≥50% of total lesion area. Withhold dose w/in the previous or next 28 days in the event of a performed or planned intraocular surgery. Not recommended in patients w/ clinical signs of irreversible ischaemic visual function loss. Concomitant use w/ other anti-VEGF. Minor influence on the ability to drive & use machines. Women of childbearing potential should use effective contraception during treatment & for at least 3 mth after last inj. Pregnancy. Not recommended during breastfeeding.
Manage Account
Change Password
Sign Out
